Sample Collection for Ongoing Research and Product Evaluation Study
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The SCORE study is a prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors. The collected specimens and information will be used to evaluate the clinical performance of Natera's molecular residual disease (MRD) testing across multiple cancer types. The study aims to assess the ability of Natera's assays to detect circulating tumor DNA (ctDNA) as a marker for disease recurrence and treatment response.
Sponsor: Natera, Inc.
You may qualify if…
- ✓ 1. 18 years of age or older.
- ✓ 2. Any patient that has an untreated primary solid malignancy within the following cohorts:
- ✓ 1. Breast cancer
- ✓ 2. Lung cancer
- ✓ 3. Muscle invasive bladder cancer
- ✓ 4. Rectal cancer
- ✓ 5. Pancreatic cancer
- ✓ 6. Ovarian cancer
You may not qualify if…
- ✕ 1. Pregnant or breastfeeding.
- ✕ 2. Prior history and treatment for any cancer within the past year or has another active cancer, with the exception of participants who have undergone surgical removal of skin squamous cell or basal cell cancers.
- ✕ 3. Has initiated postoperative systemic treatment.
- ✕ 4. At time of enrollment, has undergone or plans to undergo any ctDNA testing to assess molecular residual disease, with the exception of comprehensive genomic profiling for therapeutic selection.
- ✕ 5. History of bone marrow or organ transplant.
- ✕ 6. Serious medical conditions that may adversely affect ability to participate in the study.
Where it's recruiting
Austin
Source: ClinicalTrials.gov · NCT07318051 · last updated 2026-01-15